Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers (Q33439705)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers |
scientific article |
Statements
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers (English)
1 reference
John Heymach
1 reference
Johann de Bono
1 reference
Ramesh K Ramanathan
1 reference
Lida Mina
1 reference
Rashmi Chugh
1 reference
John Glaspy
1 reference
Saeed Rafii
1 reference
Stan Kaye
1 reference
Jasgit Sachdev
1 reference
Joshua W Henshaw
1 reference
Ashleigh Herriott
1 reference
Miranda Patterson
1 reference
Nicola J Curtin
1 reference
Lauren Averett Byers
1 reference
Zev A Wainberg
1 reference
27 February 2017
1 reference
7
1 reference
6
1 reference
620-629
1 reference
Identifiers
1 reference